Wells Fargo’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Wells Fargo’s Portfolio IMPL Stock Details IMPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-57	Closed	-$25	–	7754
2023 Q3	$25	Sell	57 -17	-23%	-$16	﹤0.01%	7131
2023 Q2	$94	Buy	74 +3	+4%	+$5	﹤0.01%	6883
2023 Q1	$99	Buy	71 +1	+1%	+$2	﹤0.01%	6942
2022 Q4	$263	Buy	70 +4	+6%	+$15	﹤0.01%	6544
2022 Q3	$0	Buy	66 +24	+57%	+$184	﹤0.01%	7669
2022 Q2	$0	Sell	42 -27,901	-100%	-$204K	﹤0.01%	7775
2022 Q1	$178K	Buy	27,943 +643	+2%	+$4.86K	﹤0.01%	5047
2021 Q4	$236K	Sell	27,300 -19,846	-42%	-$198K	﹤0.01%	5179
2021 Q3	$574K	Buy	+47,146	New	+$684K	﹤0.01%	4589

Other funds holding IMPL

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Wells Fargo's IMPL Position: Q4 2023 in Review

Wells Fargo sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 57 shares — an estimated $25 sold.

Wells Fargo first reported a position in IMPL in Q3 2021 and held it in 9 quarters. The position peaked at $574K in Q3 2021. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

Wells Fargo reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Wells Fargo sold 57 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $25.
Wells Fargo first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q3 2021 and held it in 9 quarters.
Wells Fargo's Impel Pharmaceuticals Inc. Common Stock position peaked at $574K in Q3 2021.
2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on Wells Fargo's 13F filing for Q4 2023, filed 9 Feb 2024.